Weight Management
GLPs
Retatrutide
Triple Receptor Agonist (39 Amino Acids)
Triple GIP, GLP-1 and glucagon receptor agonist developed by Eli Lilly, studied in metabolic and weight-regulation research.
Research overview
GLP-1 receptor agonists and related incretin and amylin-pathway compounds studied in metabolic research. Cagrilintide is an amylin analog, grouped here because it is studied alongside GLP-1 drugs.
Triple GIP, GLP-1 and glucagon receptor agonist developed by Eli Lilly, studied in metabolic and weight-regulation research.
Long-acting glucagon-like peptide-1 receptor agonist developed by Novo Nordisk, studied extensively in metabolic and weight-regulation research.
Dual GIP and GLP-1 receptor agonist developed by Eli Lilly, studied extensively in metabolic and glucose-regulation research.